AUTHORS
Yucai Wang, MD, PhD, Preetesh Jain, MBBS, MD, DM, PhD2, Lei Feng, MS3, Thomas Witzig, MD4, Luis E. Fayad, MD5, Urshila Durani, MD, MPH6, Sattva S Neelapu Sr, MD7, Gita Thanarajasingam, MD8, Ayushi Chauhan, MD9, Javier L. Munoz, MD, MBA10, Yu-Han Chen, MD11, David Santos, MD, MS, FACS12, Selvi Thirumurthi, MD13, Wendy Chen, PA14, Onyeka Oriabure, MS, APRN, FNP-C, AOCNP15, Robin R. Klebig, CNP, MSN16, Emily G. Brigham17, Maria Badillo, MSN, RN, OCN, CCRP18, Ashley C. Moyer19, Luis Malpica, MD20, Ranjit Nair, MD21, Jonas Paludo, MD22, Jithma Abeykoon, MD23, Ivana Micallef, MD24, Chijioke C Nze, MD, MPH25, Fateeha Furqan, MBBS26, Mark P Hamilton, MD27, Swaminathan P. Iyer, MD28, Samantha M. Robertson29, Sammy Taybi30, Misty Keller31, Chloe M. McClain32, Janet J. Guel33, Katie Bowron34, Michelle Avellaneda35, Diana R. Johnson36, Nabeel Qureshi37, Edison M. Trinidad38, Vivian Graham39, Grzegorz Nowakowski, MD40, Jason Westin, MD, MS, FACP, FASCO41, Stephen Maxted Ansell, MD, PhD42, Philippe Armand, MD43, Christopher R. Flowers Jr, MD, MS44, Michael Wang, MD45
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 Mayo Clinic, Phoenix, Arizona, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Mayo Clinic, Rochester, Minnesota, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
27 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
28 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
29 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
30 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
31 Mayo Clinic, Rochester, Minnesota, United States
32 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
33 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
34 Mayo Clinic, Rochester, Minnesota, United States
35 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
36 Mayo Clinic, Rochester, Minnesota, United States
37 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
38 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
39 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
40 Mayo Clinic, Rochester, Minnesota, United States
41 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
42 Mayo Clinic, Rochester, Minnesota, United States
43 Mayo Clinic, Rochester, Minnesota, United States
44 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
45 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Introduction: Triplet regimens combining a covalent Bruton tyrosine kinase inhibitor (BTKi), venetoclax, and an anti-CD20 antibody have demonstrated promising efficacy in previously untreated mantle cell lymphoma (MCL). Pirtobrutinib is a highly selective, non-covalent BTKi approved for relapsed/refractory MCL after prior covalent BTKi therapy. We evaluated pirtobrutinib, venetoclax, and rituximab (PVR) as frontline therapy for MCL in the phase 2 GATE1 study.
Methods: Eligible patients were adults with previously untreated MCL, ECOG PS 0-2, evaluable disease, adequate hematologic and hepatorenal function, LVEF ≥50%, and no CNS involvement. Patients received PVR induction (venetoclax started in Cycle 3) for 6-12 cycles until complete response (CR). Patients with CR confirmed by bone marrow (BM) and GI assessment proceeded to risk-adapted maintenance. High-risk disease was defined as largest tumor size ≥5 cm, or Ki-67 ≥50%, or any adverse features including blastoid/pleomorphic histology, complex karyotype, TP53 mutation/deletion, or MYC rearrangement. Intermediate-risk disease was defined as largest tumor size ≥3 to <5 cm or Ki-67 ≥30% to <50%, without adverse features. Low-risk disease was defined as all tumor sizes <3 cm, Ki-67 <30%, and no adverse features. Maintenance included pirtobrutinib and rituximab for 24 cycles, plus venetoclax for 12 cycles for low-risk patients and 24 cycles for intermediate- or high-risk patients. The primary endpoint was CR rate during PVR induction. Key secondary endpoints included overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety.
Results: From January 2025 to April 2026, 50 patients were enrolled. Median age was 67 years (range, 40-80), and 29 (58%) were ≥65 years; 36 (72%) were male, all were White, and 3 (6%) were Hispanic. MIPI was low in 16 (32%), intermediate in 22 (44%), and high in 12 (24%). Baseline features included B symptoms in 8 (16%), stage III-IV disease in 49 (98%), bone marrow involvement in 41 (82%), bulky disease (≥5 cm) in 6 (12%), and splenomegaly (>13 cm) in 15 (30%). Ki-67 was ≥30% in 14 (34%) and ≥50% in 6 (15%) of 41 patients. High-risk features included blastoid/pleomorphic histology in 5 (10%), complex karyotype in 2 of 43 (5%), TP53 mutation/deletion in 17 (34%), and MYC rearrangement in 3 of 39 (8%). By protocol-defined disease risk, 10 (20%) were low-risk, 11 (22%) intermediate-risk, and 29 (58%) high-risk.
Response by CT after Cycle 2, before venetoclax initiation, was assessed in 44 patients (6 not assessed: 2 missed CT scans, 4 had BM or GI only disease), and the ORR was 98% (43/44) and the CR rate was 27% (12/44). Response by PET/CT after Cycle 6 was evaluated in 42 patients (8 not assessed: 4 still on treatment, 4 had BM or GI only disease), and the ORR and CR rate were both 95% (40/42). Best response to induction was assessed in 48 patients (2 other patients with BM or GI only disease were pending assessment), and the best ORR was 98% (47/48) and the CR rate was 96% (46/48). Among 23 patients with post-Cycle 6 MRD assessed by clonoSEQ, the uMRD6 rate was 100%.
At data cutoff (July 13, 2026), 19 remained on induction (15 pending BM/GI confirmation of CR), 2 had progressive disease in induction, and 29 were in maintenance. After a median follow-up of 8.3 months (range, 2.5-15.6), the estimated 12-month PFS rate was 96% (95% CI, 90%-100%), and the estimated 12-month OS rate was 100%.
The most common treatment-emergent adverse events (TEAEs) were fatigue (48%), neutrophil count decreased (42%), nausea (38%), diarrhea (34%), dizziness (34%), cough (26%), abdominal pain (22%), bruising (22%), headache (22%), myalgia (20%), pain in extremity (20%), rash maculo-papular (20%), dyspnea (18%), flu like symptoms (18%), arthralgia (16%), blurred vision (16%), hypertension (16%), infusion related reaction (16%), and upper respiratory tract infection (16%). The most common grade ≥3 TEAEs were neutrophil count decreased (34%), hypertension (6%), and lymphocyte count decreased (6%). Atrial fibrillation occurred in 2 patients (4%; both grade 1), and febrile neutropenia occurred in 1 patient (2%).
Conclusions: Frontline PVR demonstrated excellent efficacy in MCL in a high-risk-enriched population, including high ORR, CR rate, and uMRD6 rate. Early PFS and OS outcomes were promising with a short follow-up. Safety profile was manageable. Longer follow-up is needed to define durability of response and survival outcomes.
DISCLOSURES
Yucai Wang, MD, PhD: LOXO Oncology - Research Funding; Incyte - Research Funding; AbbVie - Research Funding; AstraZeneca - Research Funding; Genentech - Research Funding; Innocare - Research Funding; Bristol Myers Squibb - Research Funding; Genmab - Research Funding; BeiGene - Research Funding; BeOne Medicines, Ltd - Research Funding; Merck - Research Funding; Eli Lilly and Company - Research Funding; Kite - Research Funding; AbbVie - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Innocare - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony); BeOne Medicines, Ltd - Consultancy (Includes expert testimony)